二重特異性抗体：市場規模、対象人口、競合情勢、市場予測 (2034年)

二重特異性抗体市場

当レポートでは、世界の主要7ヶ国 - 米国、欧州主要4ヶ国 (EU4：ドイツ、フランス、イタリア、スペイン) と英国、日本 - における二重特異性抗体の市場について分析し、対応可能な患者プールや、競合情勢、今後の市場動向を詳細に解説しています。

当レポートでは、二重特異性抗体を用いた患者に対する既存の治療法や、承認済み/新規の二重特異性抗体の市場規模、各々の治療法の市場シェア、二重特異性抗体による治療の対象となる患者プールなどを調査すると共に、二重特異性抗体の市場規模の現状と予測 (治療法別・適応症別；2020～2034年) を分析しております。さらに、治療パラダイムに新しいクラスを組み込む際の現時点のアンメットニーズと課題、新たな二重特異性抗体の地域ごとのアクセシビリティ・アクセプタビリティの違い、最適な機会を選別し市場の可能性を評価するための二重特異性抗体の価格設定と償還に関する洞察もカバーしています。

分析対象地域

• 米国
• EU4 (ドイツ、フランス、イタリア、スペイン)、英国
• 日本
• 分析期間：2020年～2034年

目次

第1章 主な考察

第2章 分析概要

第3章 二重特異性抗体：エグゼクティブサマリー

第4章 主な出来事

第5章 二重特異性抗体市場概要

• 二重特異性抗体の市場シェア：治療法別 (%、2023年)
• 二重特異性抗体の市場シェア：治療法別 (%、2034年)

第6章 背景と概要

第7章 対象人口

第8章 二重特異性抗体の上市済み製品

• 主な競合企業
  • 製品説明
  • 規制のマイルストーン
  • その他の開発活動
  • 進行中の治験
  • 安全性と効能
  　

第9章 二重特異性抗体の新たな治療法

• 主な競合企業
  • 製品説明
  • その他の開発活動
  • 治験
  • 安全性と効能

第10章 二重特異性抗体：主要7ヶ国の分析

• 主な調査結果
• 市場見通し
• 市場予測の主な前提条件
• 主要7ヶ国における二重特異性抗体の総市場規模
  • 主要7ヶ国における二重特異性抗体の市場規模：治療法別
  • 主要7ヶ国における二重特異性抗体の市場規模：適応症別
• 米国市場
  • 米国における二重特異性抗体の総市場規模
  • 米国における二重特異性抗体の市場規模：治療法別
• EU4・英国市場
  • EU4・英国における二重特異性抗体の総市場規模
  • EU4・英国における二重特異性抗体の市場規模：治療法別
• 日本市場
  • 日本における二重特異性抗体の総市場規模
  • 日本における二重特異性抗体の市場規模：治療法別

第11章 アンメットニーズ

第12章 SWOT分析

第13章 KOLの見解

第14章 市場アクセスと償還

• 米国
• EU4・英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本

第15章 付録

第16章 DelveInsightのサービス内容

第17章 免責事項

第18章 DelveInsightについて

List of Tables

• Table 1: Target Population in the 7MM (2020-2034)
• Table 2: Marketed Drug Key cross
• Table 3: Product 1, Clinical Trial Description, 2024
• Table 4: Product 2, Clinical Trial Description, 2024
• Table 5: Emerging Drug Key cross
• Table 6: Product 1, Clinical Trial Description, 2024
• Table 7: Product 2, Clinical Trial Description, 2024
• Table 8: Total Bispecifics Market Size in the 7MM (2020-2034)
• Table 9: Bispecifics Market Size by Therapies in the 7MM (2020-2034)
• Table 10: Bispecifics Market Size by Indication in the 7MM (2020-2034)
• Table 11: Total Bispecifics Market Size in the United States (2020-2034)
• Table 12: Bispecifics Market Size by Therapies in the United States (2020-2034)
• Table 13: Total Bispecifics Market Size in EU4 and the UK (2020-2034)
• Table 14: Bispecifics Market Size by Therapies in EU4 and the UK (2020-2034)
• Table 15: Total Bispecifics Market Size in Japan (2020-2034)
• Table 16: Bispecifics Market Size by Therapies in Japan (2020-2034)

List of Figures

• Figure 1: Target Population in the 7MM (2020-2034)
• Figure 2: Total Bispecifics Market Size in the 7MM (2020-2034)
• Figure 3: Bispecifics Market Size by Therapies in the 7MM (2020-2034)
• Figure 4: Bispecifics Market Size by Indication in the 7MM (2020-2034)
• Figure 5: Total Bispecifics Market Size in the United States (2020-2034)
• Figure 6: Bispecifics Market Size by Therapies in the United States (2020-2034)
• Figure 7: Total Bispecifics Market Size in EU4 and the UK (2020-2034)
• Figure 8: Bispecifics Market Size by Therapies in EU4 and the UK (2020-2034)
• Figure 9: Total Bispecifics Market Size in Japan (2020-2034)
• Figure 10: Bispecifics Market Size by Therapies in Japan (2020-2034)

Bispecifics Market

DelveInsight's "Bispecifics Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of Bispecifics, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

The Bispecifics market report provides insights around existing treatment practices in patients with Bispecifics, approved (if any) and emerging Bispecifics market size & market share of individual therapies, patient pool eligible for treatment with Bispecifics, along with current and forecasted 7MM Bispecifics market size from 2020-2034 by therapies and by indication. The report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new Bispecifics in different geographies, along with insights on Bispecifics pricing reimbursements to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain), and the UK
• Japan
• Study Period: 2020-2034

Bispecifics Drugs Market Overview

This segment will provide detailed information beginning with the inhibitor journey from discovery of the mutation or protein expression to its entry into clinical development followed by its upcoming commercial potential in the Bispecifics Drugs Market. This segment will dive into the different indications in Bispecifics Market Size for which the inhibitor is being developed for, which would further give insights on the potential addressable patient population. Moreover, this segment will also give a brief overview around the existing treatment paradigm of the target indications.

Bispecifics Clinical Trials

This section will give in depth information about the existing local and systemic options in the current treatment paradigm of all the potential indications, in which most of the pharmaceutical companies are actively evaluating their inhibitors. Potential of the emerging Bispecifics Market Size in changing the current clinical practice guidelines is crucial to analyze especially when it comes to real world scenario.

It will also include the relevance and importance of incorporation of biomarker testing at varying stages of the disease. It is also important to understand that implementing such tests in routine clinical practice is not uniform in different countries due to issues such as cost, accessibility, reimbursement and non-recommendation in guidelines.

Bispecifics Drug Chapters

The Bispecifics Drugs Market segment encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the Bispecifics Clinical Trial details, pharmacological action, agreements and collaborations related to Bispecifics, their approval timelines, patent details, advantages and disadvantages, latest news and press releases.

Bispecifics Marketed Drugs

The Bispecifics marketed drug section will provide detailed drug profiles of already approved therapies. Information around clinical development activities, launch timing, regulatory milestones along with safety and efficacy data of the therapy will be included.

Bispecifics Emerging Drugs

Apart from a comprehensive Bispecifics Market Forecast competitive landscape in tabular form, the emerging KRAS Inhibitor chapters provides the product details and other development activities of the emerging Bispecifics Market Size under the late and mid-stage of clinical development for various indications.

Bispecifics Drug Class Insights

The Bispecifics Drugs Market Insights section will provide comprehensive information on Bispecifics as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of Bispecifics, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs.

Bispecifics Market Outlook

This section will include details on changing Bispecifics market dynamics post initiation of clinical development activities of the inhibitor. It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial's inclusion criteria. There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space.

Bispecifics Drugs Market Uptake

This section focuses on the Bispecifics Drugs Market Uptake rate of potential Bispecifics already launched and expected to be launched in the market during 2020-2034, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Bispecifics Pipeline Development Activities

The Bispecifics Market report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Bispecifics Pipeline Development Activities

The Bispecifics Market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Bispecifics.

KOL Views

To keep up with current and future market trends, we incorporate Key physicians, Therapy Area Researcher's, and other Industry Experts' opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on Bispecifics' incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Bispecifics Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the cost analysis and existing and evolving treatment landscape.

Bispecifics Market Access and Reimbursement

This section will include Bispecifics market insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy.

Moreover, this section will also provide details on reimbursement of approved therapy, if any.

Scope of the Bispecifics Market Report

• The Bispecifics Market report covers a segment of key events, an executive summary, target patient pool, epidemiology and Bispecifics market forecast, information around patient journey and varying biomarker testing rates
• Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on Bispecifics addressable patient pool
• A detailed review of the Bispecifics market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM Bispecifics market.
• Bispecifics Market Size of Inhibitors by therapies and indication will be provided

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Bispecifics

4. Key Events

5. Bispecifics Market Overview At A Glance

• 5.1. Market Share (%) Distribution of Bispecifics By Therapy in 2023
• 5.2. Market Share (%) Distribution of Bispecifics By Therapy in 2034

6. Background And Overview

7. Target Population

8. Bispecifics Marketed Drugs

• 8.1. Key Competitors
• 8.2. Company 1: Product 1
  • 8.2.1. Product Description
  • 8.2.2. Regulatory Milestones
  • 8.2.3. Other Developmental Activities
  • 8.2.4. Ongoing Clinical Development
  • 8.2.5. Safety and Efficacy
• 8.3. Company 2: Product 2
  • 8.3.1. Product Description
  • 8.3.2. Regulatory Milestones
  • 8.3.3. Other Developmental Activities
  • 8.3.4. Ongoing Clinical Development
  • 8.3.5. Safety and Efficacy

9. Bispecifics Emerging Drugs

• 9.1. Key Competitors
• 9.2. Company 1: Product 1
  • 9.2.1. Product Description
  • 9.2.2. Other Development Activities
  • 9.2.3. Clinical Development
    • 9.2.3.1. Clinical Trials Information
  • 9.2.4. Safety and Efficacy
• 9.3. Company 2: Product 2
  • 9.3.1. Product Description
  • 9.3.2. Other Development Activities
  • 9.3.3. Clinical Development
    • 9.3.3.1. Clinical Trials Information
  • 9.3.4. Safety and Efficacy

10. Bispecifics: The 7MM Analysis

• 10.1. Key Findings
• 10.2. Market Outlook
• 10.3. Key Market Forecast Assumptions
• 10.4. Total Market Size of Bispecifics in the 7MM
  • 10.4.1. Market Size of Bispecifics By Therapies In the 7MM
  • 10.4.2. Market Size of Bispecifics By Indication In the 7MM
• 10.6. United States Market
  • 10.6.1. Total Market Size of Bispecifics in the United States
  • 10.6.2. Market Size of Bispecifics By Therapies in the United States
• 10.7. EU4 and the UK Market
  • 10.7.1. Total Market Size of Bispecifics in EU4 and the UK
  • 10.7.2. Market Size of Bispecifics By Therapies in EU4 and the UK
• 10.8. Japan Market
  • 10.8.1. Total Market Size of Bispecifics in Japan
  • 10.8.2. Market Size of Bispecifics By Therapies in Japan

11. Unmet Needs

12. SWOT Analysis

13. KOL Views

14. Market Access and Reimbursement

• 14.1. United States
  • 14.1.1. Centre for Medicare & Medicaid Services (CMS)
• 14.2. EU4 and the UK
  • 14.2.1. Germany
  • 14.2.2. France
  • 14.2.3. Italy
  • 14.2.4. Spain
  • 14.2.5. United Kingdom
• 14.3. Japan
  • 14.3.1. MHLW

15. Appendix

• 15.1. Bibliography
• 15.2. Report Methodology

16. Delveinsight Capabilities

17. Disclaimer

18. About DelveInsight